Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study

Figure 2

Flow diagram of this study. In total, 75 patients with type 2 diabetes hospitalized during the study periods. Of these, 57 patients were excluded due to exclusion criteria. Fifteen patients were enrolled, and 3 patients dropped out. Finally, 12 patients completed the study. T2DM: type 2 diabetes; DPP-4 inhibitor: dipeptidyl peptidase-4 inhibitor; GLP-1RA: glucagon-like peptide-1 receptor agonist.